View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsRenovacor 将来の成長Future 基準チェック /06主要情報-93.6%収益成長率-35.45%EPS成長率Biotechs 収益成長25.1%収益成長率90.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日n/a今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.すべての更新を表示Recent updatesお知らせ • Dec 02Renovacor Requests NYSE to Remove its Shares from ListingOn December 1, 2022 (the Closing Date"), Rocket Pharmaceuticals, Inc. ("Rocket" or Parent"), completed the previously announced acquisition of Renovacor, Inc., a Delaware corporation ("the Company," Renovacor") pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022 (the Merger Agreement"), by and among Rocket, Renovacor, Zebrafish Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Rocket (Merger Sub I"), and Zebrafish Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Rocket (Merger Sub II"). On December 1, 2022, in connection with the consummation of the Mergers, the Company (i) notified The New York Stock Exchange American LLC (the NYSE") of the consummation of the Mergers and (ii) requested that the NYSE remove Company Shares and the Company Public Warrants from listing and file a Form 25 with the SEC to report the delisting of the Company Shares and Company Public Warrants from the NYSE. Upon effectiveness of the Form 25, the Company intends to file with the SEC a Certification and Notice of Termination on Form 15 with the SEC to suspend Renovacor's reporting obligations under Sections 13 and 15(d) of the Securities Exchange Act of 1934, as amended.Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 22Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million on September 19, 2022. Under the terms of the transaction, Renovacor shareholders will receive approximately 0.1676 shares of Rocket in exchange for each of their shares in Renovacor and are expected to own approximately 4.6% percent of Rocket equity on a fully diluted basis immediately following the closing of the transaction. The exchange ratio implies an equity deal value of approximately $53 million based on fully diluted shares outstanding and the acceleration and vesting of all earnout shares, or $2.60 per share of Renovacor. The exchange ratio is subject to adjustment based on Renovacor net cash at closing. Rocket shall pay a termination fee of $1.74 million to Renovacor and Renovacor shall pay a termination fee of $1.74 million to Rocket. RTW Investments, LP, a significant shareholder of both Rocket and Renovacor, has entered into a voting agreement with Renovacor, pursuant to which they have agreed, among other things, and subject to the terms and conditions of the agreement. The deal is subject to approval by Renovacor and Rocket shareholders, receipt of any required customary regulatory approvals, the required approvals by Rocket’s and Renovacor’s stockholders, the Rocket Shares to be issued in the First Merger being approved for listing on Nasdaq as of the closing, the Registration Statement having become effective, the waiting period under the HSR Act shall have expired or been terminated and the satisfaction of other customary closing conditions. The boards of directors of both companies have unanimously approved the transaction, which is currently expected to close by the first quarter of 2023. SVB Securities is serving as exclusive financial advisor and fairness opinion provider and John T. Haggerty, William D. Collins and Sarah Ashfaq of Goodwin Procter LLP is serving as legal counsel to Rocket. Wells Fargo Securities is serving as exclusive financial advisor and fairness opinion provider and Rachael Bushey and Jennifer Porter of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Renovacor.お知らせ • Jul 13Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic CardiomyopathyRenovacor, Inc. announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program, Renovacor has entered into a research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI). The terms of the research agreement grant Renovacor an option for an exclusive license to inventions generated from the collaboration. The research collaboration will focus on a protein discovered by University of Utah scientists that has the potential to address multiple genetic segments of ACM. The new program is being developed as an AAV-based gene therapy to treat potentially life-threatening arrhythmias associated with the disease by restoring gap junction protein trafficking and gap junction communication between heart muscle cells. The program will be developed for the three largest genetic segments of ACM: plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmoplakin (DSP) associated ACM. Currently available treatment options do not address the trafficking defects central to each of the these genetically-driven forms of ACM. The collaboration leverages positive proof-of-concept data generated in a genetic mouse model of ACM that was performed by the Shaw Lab, led by Robin Shaw, M.D., Ph.D., Professor of Medicine at the University of Utah and Director of the CVRTI. These data demonstrate restoration of gap junction trafficking to the intercalated disc and a significant reduction in premature ventricular contractions (PVCs). PVCs are a hallmark of ACM and key drivers of potentially lethal ventricular arrhythmias. Arrhythmogenic cardiomyopathy (ACM) is a heritable heart muscle disorder that can affect the left and right ventricle. It is characterized by a heightened risk of potentially lethal ventricular arrhythmias, fibrofatty replacement of myocardial tissue, and in some patients, heart failure.(1,2) It is recognized as a disease of the desmosome, with well-defined genetic drivers. The prevalence of ACM is estimated to range from 1 case in 1,000 persons to 1 case in 5,000, with an average age of diagnosis of approximately 30 years.(1-3) Current treatment options aim to prevent potentially life-threatening arrhythmias and progression to end-stage disease, but they do not target the underlying genetics or disease biology and, as such, patients can continue to experience serious breakthrough events.お知らせ • Jun 26+ 1 more updateRenovacor Appoints Wendy Dicicco as the Chief Financial OfficerOn June 3, 2022, the Renovacor, Inc. reported that its Board of Directors (the “Board”) had appointed Wendy DiCicco as the Company’s Chief Financial Officer. Under the CFO Agreement, Ms. DiCicco will provide services to the Company as its Chief Financial Officer in a non-employee capacity, effective as of June 17, 2022 (Effective Date).お知らせ • Jun 05+ 1 more updateRenovacor, Inc. Announces CFO ChangesOn May 30, 2022, Fred Driscoll, the Chief Financial Officer of Renovacor, Inc. notified the Company of his decision to resign effective as of June 17, 2022 (the “Effective Date”). Mr. Driscoll resigned for personal reasons and not as a result of any disagreement with the Company or its independent registered public accountants on any matter relating to the Company’s financial or accounting operations, policies or practices. On June 2, 2022, the Board of Directors (the “Board”) of the Company appointed Wendy DiCicco, the Company’s former Interim Chief Financial Officer, as Chief Financial Officer, effective as of the Effective Date. Ms. DiCicco will assume the duties of the principal financial officer of the Company as of the Effective Date. Ms. DiCicco served as the Company’s Interim Chief Financial Officer from September 2019 to March 2022, after which she continued to serve in a consulting capacity. In addition, since November 2018 she has served as an executive board advisory consultant for Board Advantage, LLC. Prior to this time, she was the Chief Operating and Financial Officer of Centinel Spine from August 2017 to October 2018. She previously served as President and Chief Operating Officer of Camber Spine Technologies from November 2014 to July 2017, and has held Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Ms. DiCicco has served on the boards of directors of SWK Holdings since February 2022, Sincerus Pharmaceuticals since July 2021, Imvax, Inc. since July 2020, ExpressCells since March 2020 and EyePoint Pharmaceuticals since July 2019. She previously served on the boards of directors of II-VI, Inc. from 2006 until August 2017 as well as the boards of CannaPharma Rx and Syncardia Systems. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA.お知らせ • Jun 02Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of CardiologyRenovacor, Inc. announced the publication of the results of a preclinical study demonstrating cardiac transduction with low-doses of REN-001 delivered via retrograde coronary sinus infusion (RCSI) in healthy Yucatan pigs. REN-001 is an AAV-based gene therapy designed to directly address the underlying cause of BAG3-associated dilated cardiomyopathy (BAG3-DCM) by using a validated AAV9 capsid to deliver a functional copy of the BAG3 gene to cardiac tissue. In the pilot Yucatan pig study featured in JACC: BTS, low doses (<1e13 vector genome (vg) per kilogram (kg)) of REN-001 delivered locally to the heart using RCSI resulted in each evaluated cardiomyocyte containing, on average, at least one copy of the delivered BAG3 gene (i.e., vector copy number threshold =1). The study also demonstrated diffuse transduction patterns across multiple regions of the heart and documented the presence of vector mRNA /transcript. Additionally, all animals tolerated the procedure without evidence of heart injury (e.g., arrythmia, presence of myocardial scar, or coronary sinus injury at necropsy). The pilot Yucatan pig study published in JACC: BTS included three dose groups. Group A evaluated a 1.46e12 vg/kg dose, Group B evaluated a 3.45e12 vg/kg dose and Group C evaluated a 7.58e12 vg/kg dose (based on median pig weights for each group). Levels of vector genomes and corresponding RNA transcripts were quantified.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 15Renovacor, Inc., Annual General Meeting, May 25, 2022Renovacor, Inc., Annual General Meeting, May 25, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect three director nominees that are set forth in the attached 2022 Annual Meeting Proxy Statement, or the Proxy Statement, to serve as Class I directors, whose term will expire in 2025; to ratify the appointment of Ernst & Young LLP, or EY, as independent registered public accounting firm for the 2022 fiscal year; and to transact any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.お知らせ • Mar 29Renovacor, Inc. Appoints Fred Driscoll as Chief Financial OfficerRenovacor, Inc. announced the appointment of Fred Driscoll as Chief Financial Officer (CFO). Mr. Driscoll joins Renovacor with over 25 years of executive experience in the biotech industry. He most recently served as the CFO of Flexion Therapeutics (Flexion), where he led the company through a successful $75 million initial public offering in 2014 and subsequently raised an additional $450 million in capital for the company.Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Scientific Advisory Board & Director Anne Prener was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.業績と収益の成長予測NYSEAM:RCOR - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2024N/AN/AN/AN/A112/31/2023N/A-51N/AN/A412/31/2022N/A-26N/AN/A49/30/2022N/A-13-31-30N/A6/30/2022N/A-6-28-28N/A3/31/2022N/A-6-22-22N/A12/31/2021N/A-14-16-16N/A9/30/2021N/A-14-10-10N/A6/30/2021N/A-7-6-6N/A3/31/2021N/A-4-4-4N/A12/31/2020N/A-3-3-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RCOR今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: RCOR今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: RCOR今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: RCOR来年は収益がないと予測されています。高い収益成長: RCOR来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RCORの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/12/01 21:44終値2022/11/30 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Renovacor, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Jack AllenBairdYun ZhongBTIGYevgeniya LivshitsChardan Capital Markets, LLC
Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.
お知らせ • Dec 02Renovacor Requests NYSE to Remove its Shares from ListingOn December 1, 2022 (the Closing Date"), Rocket Pharmaceuticals, Inc. ("Rocket" or Parent"), completed the previously announced acquisition of Renovacor, Inc., a Delaware corporation ("the Company," Renovacor") pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022 (the Merger Agreement"), by and among Rocket, Renovacor, Zebrafish Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Rocket (Merger Sub I"), and Zebrafish Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Rocket (Merger Sub II"). On December 1, 2022, in connection with the consummation of the Mergers, the Company (i) notified The New York Stock Exchange American LLC (the NYSE") of the consummation of the Mergers and (ii) requested that the NYSE remove Company Shares and the Company Public Warrants from listing and file a Form 25 with the SEC to report the delisting of the Company Shares and Company Public Warrants from the NYSE. Upon effectiveness of the Form 25, the Company intends to file with the SEC a Certification and Notice of Termination on Form 15 with the SEC to suspend Renovacor's reporting obligations under Sections 13 and 15(d) of the Securities Exchange Act of 1934, as amended.
Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 22Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million on September 19, 2022. Under the terms of the transaction, Renovacor shareholders will receive approximately 0.1676 shares of Rocket in exchange for each of their shares in Renovacor and are expected to own approximately 4.6% percent of Rocket equity on a fully diluted basis immediately following the closing of the transaction. The exchange ratio implies an equity deal value of approximately $53 million based on fully diluted shares outstanding and the acceleration and vesting of all earnout shares, or $2.60 per share of Renovacor. The exchange ratio is subject to adjustment based on Renovacor net cash at closing. Rocket shall pay a termination fee of $1.74 million to Renovacor and Renovacor shall pay a termination fee of $1.74 million to Rocket. RTW Investments, LP, a significant shareholder of both Rocket and Renovacor, has entered into a voting agreement with Renovacor, pursuant to which they have agreed, among other things, and subject to the terms and conditions of the agreement. The deal is subject to approval by Renovacor and Rocket shareholders, receipt of any required customary regulatory approvals, the required approvals by Rocket’s and Renovacor’s stockholders, the Rocket Shares to be issued in the First Merger being approved for listing on Nasdaq as of the closing, the Registration Statement having become effective, the waiting period under the HSR Act shall have expired or been terminated and the satisfaction of other customary closing conditions. The boards of directors of both companies have unanimously approved the transaction, which is currently expected to close by the first quarter of 2023. SVB Securities is serving as exclusive financial advisor and fairness opinion provider and John T. Haggerty, William D. Collins and Sarah Ashfaq of Goodwin Procter LLP is serving as legal counsel to Rocket. Wells Fargo Securities is serving as exclusive financial advisor and fairness opinion provider and Rachael Bushey and Jennifer Porter of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Renovacor.
お知らせ • Jul 13Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic CardiomyopathyRenovacor, Inc. announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program, Renovacor has entered into a research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI). The terms of the research agreement grant Renovacor an option for an exclusive license to inventions generated from the collaboration. The research collaboration will focus on a protein discovered by University of Utah scientists that has the potential to address multiple genetic segments of ACM. The new program is being developed as an AAV-based gene therapy to treat potentially life-threatening arrhythmias associated with the disease by restoring gap junction protein trafficking and gap junction communication between heart muscle cells. The program will be developed for the three largest genetic segments of ACM: plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmoplakin (DSP) associated ACM. Currently available treatment options do not address the trafficking defects central to each of the these genetically-driven forms of ACM. The collaboration leverages positive proof-of-concept data generated in a genetic mouse model of ACM that was performed by the Shaw Lab, led by Robin Shaw, M.D., Ph.D., Professor of Medicine at the University of Utah and Director of the CVRTI. These data demonstrate restoration of gap junction trafficking to the intercalated disc and a significant reduction in premature ventricular contractions (PVCs). PVCs are a hallmark of ACM and key drivers of potentially lethal ventricular arrhythmias. Arrhythmogenic cardiomyopathy (ACM) is a heritable heart muscle disorder that can affect the left and right ventricle. It is characterized by a heightened risk of potentially lethal ventricular arrhythmias, fibrofatty replacement of myocardial tissue, and in some patients, heart failure.(1,2) It is recognized as a disease of the desmosome, with well-defined genetic drivers. The prevalence of ACM is estimated to range from 1 case in 1,000 persons to 1 case in 5,000, with an average age of diagnosis of approximately 30 years.(1-3) Current treatment options aim to prevent potentially life-threatening arrhythmias and progression to end-stage disease, but they do not target the underlying genetics or disease biology and, as such, patients can continue to experience serious breakthrough events.
お知らせ • Jun 26+ 1 more updateRenovacor Appoints Wendy Dicicco as the Chief Financial OfficerOn June 3, 2022, the Renovacor, Inc. reported that its Board of Directors (the “Board”) had appointed Wendy DiCicco as the Company’s Chief Financial Officer. Under the CFO Agreement, Ms. DiCicco will provide services to the Company as its Chief Financial Officer in a non-employee capacity, effective as of June 17, 2022 (Effective Date).
お知らせ • Jun 05+ 1 more updateRenovacor, Inc. Announces CFO ChangesOn May 30, 2022, Fred Driscoll, the Chief Financial Officer of Renovacor, Inc. notified the Company of his decision to resign effective as of June 17, 2022 (the “Effective Date”). Mr. Driscoll resigned for personal reasons and not as a result of any disagreement with the Company or its independent registered public accountants on any matter relating to the Company’s financial or accounting operations, policies or practices. On June 2, 2022, the Board of Directors (the “Board”) of the Company appointed Wendy DiCicco, the Company’s former Interim Chief Financial Officer, as Chief Financial Officer, effective as of the Effective Date. Ms. DiCicco will assume the duties of the principal financial officer of the Company as of the Effective Date. Ms. DiCicco served as the Company’s Interim Chief Financial Officer from September 2019 to March 2022, after which she continued to serve in a consulting capacity. In addition, since November 2018 she has served as an executive board advisory consultant for Board Advantage, LLC. Prior to this time, she was the Chief Operating and Financial Officer of Centinel Spine from August 2017 to October 2018. She previously served as President and Chief Operating Officer of Camber Spine Technologies from November 2014 to July 2017, and has held Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Ms. DiCicco has served on the boards of directors of SWK Holdings since February 2022, Sincerus Pharmaceuticals since July 2021, Imvax, Inc. since July 2020, ExpressCells since March 2020 and EyePoint Pharmaceuticals since July 2019. She previously served on the boards of directors of II-VI, Inc. from 2006 until August 2017 as well as the boards of CannaPharma Rx and Syncardia Systems. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA.
お知らせ • Jun 02Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of CardiologyRenovacor, Inc. announced the publication of the results of a preclinical study demonstrating cardiac transduction with low-doses of REN-001 delivered via retrograde coronary sinus infusion (RCSI) in healthy Yucatan pigs. REN-001 is an AAV-based gene therapy designed to directly address the underlying cause of BAG3-associated dilated cardiomyopathy (BAG3-DCM) by using a validated AAV9 capsid to deliver a functional copy of the BAG3 gene to cardiac tissue. In the pilot Yucatan pig study featured in JACC: BTS, low doses (<1e13 vector genome (vg) per kilogram (kg)) of REN-001 delivered locally to the heart using RCSI resulted in each evaluated cardiomyocyte containing, on average, at least one copy of the delivered BAG3 gene (i.e., vector copy number threshold =1). The study also demonstrated diffuse transduction patterns across multiple regions of the heart and documented the presence of vector mRNA /transcript. Additionally, all animals tolerated the procedure without evidence of heart injury (e.g., arrythmia, presence of myocardial scar, or coronary sinus injury at necropsy). The pilot Yucatan pig study published in JACC: BTS included three dose groups. Group A evaluated a 1.46e12 vg/kg dose, Group B evaluated a 3.45e12 vg/kg dose and Group C evaluated a 7.58e12 vg/kg dose (based on median pig weights for each group). Levels of vector genomes and corresponding RNA transcripts were quantified.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 15Renovacor, Inc., Annual General Meeting, May 25, 2022Renovacor, Inc., Annual General Meeting, May 25, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect three director nominees that are set forth in the attached 2022 Annual Meeting Proxy Statement, or the Proxy Statement, to serve as Class I directors, whose term will expire in 2025; to ratify the appointment of Ernst & Young LLP, or EY, as independent registered public accounting firm for the 2022 fiscal year; and to transact any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
お知らせ • Mar 29Renovacor, Inc. Appoints Fred Driscoll as Chief Financial OfficerRenovacor, Inc. announced the appointment of Fred Driscoll as Chief Financial Officer (CFO). Mr. Driscoll joins Renovacor with over 25 years of executive experience in the biotech industry. He most recently served as the CFO of Flexion Therapeutics (Flexion), where he led the company through a successful $75 million initial public offering in 2014 and subsequently raised an additional $450 million in capital for the company.
Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Scientific Advisory Board & Director Anne Prener was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.